autologous muc1-activated t-cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2022 (NCT05411497)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1Immunity, passive
MUC1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06483048 | Phase 1 | Sep 20, 2024 | Mayo Clinic |
| NCT05411497 | Phase 1 | Jun 20, 2022 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 2 | 2 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1